首页 › 结直肠癌 › 得克萨斯州 › Fort Worth
Fort Worth TX 结直肠癌临床试验
7项针对 结直肠癌的研究正在 Fort Worth及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
招募中2 期
- START Dallas Fort Worth, Fort Worth
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
招募中1 期
- START Center for Clinical Research, Fort Worth
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
招募中3 期
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
招募中3 期
- Clinical Study Site, Fort Worth
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
招募中2 期
- The Center For Cancer And Blood Disorders /ID# 278512, Fort Worth
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
招募中1 期
- START Dallas Fort Worth, LLC, Fort Worth
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
招募中1 期
- START Dallas Fort Worth, LLC, Fort Worth
其他城市的 结直肠癌试验
- Houston, TX102 项研究
- New York City, NY78 项研究
- Nashville, TN69 项研究
- Boston, MA63 项研究
- Los Angeles, CA59 项研究
- Arlington, VA52 项研究
- St. Louis, MO50 项研究
- San Antonio, TX46 项研究
- Philadelphia, PA44 项研究
- Grand Rapids, MI40 项研究
- Baldwin Park, CA37 项研究
- Chicago, IL34 项研究
Fort Worth的其他研究
- 非小细胞肺癌18 项研究
- 卵巢癌17 项研究
- 子宫内膜癌12 项研究
- 乳腺癌12 项研究
- 癌症（所有类型）9 项研究
- 前列腺癌9 项研究
- 三阴性乳腺癌7 项研究
- 黄斑变性7 项研究
- 溃疡性结肠炎7 项研究
- 肾癌（肾细胞癌）7 项研究
- 心力衰竭7 项研究
- 转移性癌症7 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。